Clinical Studies and Thrombin Generation in Patients Homozygous or Heterozygous for the G20210A Mutation in the Prothrombin Gene
- 1 August 1998
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 18 (8), 1287-1291
- https://doi.org/10.1161/01.atv.18.8.1287
Abstract
Abstract —A genetic variation in the prothrombin gene, the G→A transition at nucleotide 20210, is a risk factor for venous thrombosis in heterozygotes and is associated with increased prothrombin activity. The homozygous phenotype and the extent of thrombin generation in heterozygous and homozygous subjects are unknown. We investigated a family that included 2 homozygous and 5 heterozygous carriers of the 20210 A allele. The homozygous propositus and his presumably heterozygous father suffered from deep-vein thrombosis. His presumably heterozygous mother and his homozygous sister had recurrent phlebitis at a young age. The remaining 5 affected family members are still asymptomatic. We studied thrombin generation in the family and in 22 unrelated carriers of the 20210 A allele by measuring (1) prothrombin fragment F1+2 (F1+2) as an index of ongoing thrombin generation and (2) the endogenous thrombin potential (ETP) as an index of the possible thrombin-forming capacity. Their F1+2 levels were not different from those of age-matched controls, and thus, ongoing hemostatic system activation was not detectable. A significantly increased ETP was found in the heterozygous carriers of the 20210A allele compared with the controls (527.8±114.9 versus 387±50.1 nmol/L · min, P <0.0001). In the 2 homozygotes, the ETP was almost twice (639 and 751 nmol/L · min, respectively) as high as in the controls. We conclude that homozygosity for the G20210A mutation in the prothrombin gene is associated with a severe, albeit more benign, thrombotic diathesis compared with homozygosity for deficiencies of antithrombin, protein C, or protein S. In carriers of the 20210 A allele, the pathomechanisms leading to thrombosis should be sought in the higher amounts of thrombin that may be formed once thrombin generation is triggered, rather than in ongoing thrombin generation in vivo.Keywords
This publication has 10 references indexed in Scilit:
- The Routine Determination of the Endogenous Thrombin Potential, First Results in Different Forms of Hyper- and HypocoagulabilityThrombosis and Haemostasis, 1997
- Elevated Levels of Prothrombin Activation Fragment 1+2 in Plasma from Patients with Heterozygous Arg506 to Gin Mutation in the Factor V Gene (APC-Resistance) and/or Inherited Protein S DeficiencyThrombosis and Haemostasis, 1996
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiencyBlood, 1993
- Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Homozygous protein S deficiency in an infant with purpura fulminansThe Journal of Pediatrics, 1990
- Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiencyBlood, 1988
- The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activationBlood, 1987
- Homozygous Protein C Deficiency Manifested by Massive Venous Thrombosis in the NewbornThe New England Journal of Medicine, 1984
- INHERITED PROTEIN C DEFICIENCY AND COUMARIN-RESPONSIVE CHRONIC RELAPSING PURPURA FULMINANS IN A NEWBORN INFANTThe Lancet, 1983